PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7394]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7395]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7396]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7397]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7398]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7399]
van Helvoort M. Int Clin Psychopharmacol. Sep 2019; 34(5): 269-272 Pubmed [9131]
van Hoppe S. Pharmacol Res. Aug 2019; 146: 104297 Pubmed [11487]
van Hoppe S. Pharmacol Res. Jun 2017; 120: 43-50 Pubmed [7756]
Van Kammen DP. Psychopharmacologia. Nov 1975; 44(3): 215-24 Pubmed [1743]
van Kan HJ. Biopharm Drug Dispos. Apr 2008; 29(3): 139-44 Pubmed [11375]
van Laar MW. Psychopharmacology (Berl). Aug 2002; 162(4): 351-63 Pubmed [11246]
van Leeuwen DJ. Ned Tijdschr Geneeskd. Mar 1986; 130(12): 548-50 Pubmed [6091]
van Luin M. AIDS. May 2010; 24(8): 1223-6 Pubmed [6421]
van Luin M. J Acquir Immune Defic Syndr. Sep 2010; 55(1): 82-6 Pubmed [7378]
van Luin M. J Clin Pharmacol. Oct 2009; 49(10): 1220-7 Pubmed [2953]
van Maarseveen EM. AIDS Patient Care STDS. Oct 2012; 26(10): 568-81 Pubmed [8981]
van Meerten E. Drug Saf. Mar 1995; 12(3): 168-82 Pubmed [7341]
van Nuland M. Prostate Cancer Prostatic Dis. Jun 2020; 23(2): 244-251 Pubmed [12403]
van Praag HM. Biol Psychiatry. Feb 1987; 22(2): 205-12 Pubmed [8281]
Van Rooij J. Br J Clin Pharmacol. Jun 1993; 35(6): 661-3 Pubmed, Volltext, DOI [8584]
van Seyen M. Clin Pharmacol Ther. Nov 2019; 106(5): 1093-1098 Pubmed [8058]
Van Slooten AD. DICP. Jun 1991; 25(6): 578-82 Pubmed [5833]
Van Strater AC. Int Clin Psychopharmacol. Mar 2012; 27(2): 121-4 Pubmed [1129]
van Waterschoot RA. Br J Pharmacol. Jul 2010; 160(5): 1224-33 Pubmed, Volltext, DOI [8777]
van Wieringen A. Clin Pharmacokinet. Apr 1990; 18(4): 332-8 Pubmed [2451]
van Wieringen A. Neurology. Sep 1983; 33(9): 1227-8 Pubmed [9275]
van Zuilekom S. Tijdschr Psychiatr. Jan 2013; 55(12): 955-9 Pubmed [6999]
van Zwieten PA. Arch Int Pharmacodyn Ther. Mar 1975; 214(1): 12-30 Pubmed [1941]
Vanakoski J. Eur J Clin Pharmacol. Jan 1996; 50(6): 501-8 Pubmed [1877]
Vandel et al. Pharm Res 1995;31(6):347-353 [1025]
Vandel et al. Therapie (1990) 45, 21 [1027]
Vandel P. Encephale. Jan 1999; 25(1): 67-71 Pubmed [3182]
Vandel P. Encephale. Nov 1999; 25(6): 672-3 Pubmed [10122]
Vandel P. Hum Psychopharmacol. Jul 2004; 19(5): 293-8 Pubmed [8213]
Vandel S. Pharmacol Res. Jun 1995; 31(6): 347-53 Pubmed [1480]
Vandel S. Ther Drug Monit. Jan 1988; 10(4): 386-9 Pubmed [2421]
Vandel. Therapie (1990) 45, 21 [544]
VandenBrink BM. Drug Metab Dispos. Jan 2012; 40(1): 47-53 Pubmed [3488]
Vandenbussche C. Arch Toxicol. Apr 2018; 92(4): 1539-1550 Pubmed [7889]
Vandevelde C. Pharmacotherapy. Jan 1991; 11(1): 88-9 Pubmed [6210]
VanLandingham KE. J Clin Pharmacol. Oct 2020; 60(10): 1304-1313 Pubmed, Volltext, DOI [9843]
VARAGIC V. Arch Int Pharmacodyn Ther. Apr 1958; 114(3-4): 426-34 Pubmed [9402]
Varanese S. Mov Disord. Mar 2010; 25(4): 508-10 Pubmed [9917]
Vardar MK, Kovalak EE. Bagcilar Med Bul. Sep 2022; 7: 288–290 Pubmed [13449]
Varhe A. Br J Clin Pharmacol. Apr 1996; 41(4): 319-23 Pubmed, Volltext, DOI [2398]
Varhe A. Br J Clin Pharmacol. Oct 1996; 42(4): 465-70 Pubmed, Volltext, DOI [2394]
Varhe A. Clin Pharmacol Ther. Apr 1996; 59(4): 369-75 Pubmed [2400]
Varhe A. Clin Pharmacol Ther. Dec 1994; 56(6 Pt 1): 601-7 Pubmed [2396]
Varis et al. Clin Pharmacol Therap 2000;68(5):487-494 [2972]
Varis T. Clin Pharmacol Ther. Nov 2000; 68(5): 487-94 Pubmed [4493]
Varsaldi F. Eur J Clin Pharmacol. Sep 2006; 62(9): 721-6 Pubmed [113]
Vasconcelos GS. Schizophr Res. Jul 2015; 165(2-3): 163-70 Pubmed [11751]
Vasiliou V. Acta Pharmacol Toxicol (Copenh). May 1986; 58(5): 305-10 Pubmed [6828]
Vasquez E. Clin Transplant. Apr 2001; 15(2): 95-9 Pubmed [3089]
Vautier S. Eur J Pharm Sci. Feb 2006; 27(2-3): 167-74 Pubmed [58]
Vaz J et al.,Indian J Clin Pharmacol (1998) 45, 176-8 [2429]
Vaz-Da-Silva M. J Clin Pharmacol. Feb 2012; 52(2): 222-33 Pubmed [9193]
Vázquez M. Case Rep Med. Aug 2018; 2018: 5371854 Pubmed, Volltext, DOI [8138]
Vazquez SR. Hematology Am Soc Hematol Educ Program. Nov 2018; 2018(1): 339-347 Pubmed [12761]
Vcev A. Acta Med Croatica. Jan 1998; 52(4-5): 209-14 Pubmed [7689]
Vcev A. Helicobacter. Mar 1999; 4(1): 54-7 Pubmed [7688]
Vecchia DD. Behav Brain Res. Apr 2018; 342: 1-10 Pubmed [12319]
Vecchia DD. Brain Res Bull. Mar 2021; 168: 63-73 Pubmed [12313]
Veenstra JA. Gen Comp Endocrinol. Jul 2019; 278: 3-11 Pubmed [8207]
Veenstra-VanderWeele J. J Child Adolesc Psychopharmacol. Apr 2010; 20(2): 163-5 Pubmed [11460]
Veilleux O. CMAJ. Sep 2017; 189(37): E1188-E1191 Pubmed, Volltext, DOI [6366]
Velázquez H. Ann Intern Med. Aug 1993; 119(4): 296-301 Pubmed [10986]
Veldkamp AI. J Infect Dis. Jul 2001; 184(1): 37-42 Pubmed [7105]
Vella JP. Am J Kidney Dis. Feb 1998; 31(2): 320-3 Pubmed [1466]
Vella S. Antivir Ther. Aug 1996; 1(3): 129-40 Pubmed [6267]
Vella T. J Pharm Pharmacol. Jun 2014; 66(6): 747-59 Pubmed [1977]
Velozo CT. Crit Rev Anal Chem. May 2021; : 1-17 Pubmed [11648]
Venkatakrishnan K. Drug Metab Dispos. Jun 2005; 33(6): 845-52 Pubmed [1232]
Venkatakrishnan K. J Clin Pharmacol. Feb 1998; 38(2): 112-21 Pubmed [38]
Venkatakrishnan K. J Clin Pharmacol. Oct 2001; 41(10): 1043-54 Pubmed [4230]
Venkatesan K. Clin Pharmacokinet. Jan 1992; 22(1): 47-65 Pubmed [6259]
Venkatesan V. Clin Neuropharmacol. Mar 2019; 42(2): 64-65 Pubmed [7573]
Ventafridda et al. Lancet (1987) i, 1204 [1032]
Verbeeck RK. Clin Pharmacokinet. Jul 1990; 19(1): 44-66 Pubmed [8459]
Verbist L. Arzneimittelforschung. Jan 1979; 29(12a): 1962-6 Pubmed [12362]
Verdoux H. Schizophr Res. Sep 2019; 211: 1-9 Pubmed [8038]
Vergara-López S. Med Clin (Barc). Nov 2004; 123(16): 639 Pubmed [5810]
Verhagen CA. Br J Clin Pharmacol. Feb 1994; 37(2): 193-7 Pubmed, Volltext [5469]
Verheijden NA. Neth J Med. Mar 2016; 74(3): 133-5 Pubmed [8887]
Vermeir M. Drug Metab Dispos. Apr 2008; 36(4): 769-79 Pubmed [245]
Vermeir M. Drug Metab Dispos. Apr 2009; 37(4): 809-20 Pubmed [4217]
Vermes A. Am J Cardiovasc Drugs. Jan 2004; 4(4): 247-55 Pubmed [205]
Vermes A. J Antimicrob Chemother. Aug 2000; 46(2): 171-9 Pubmed [7338]
Vermunt M. Clin Pharmacol. Jan 2021; 13: 21-32 Pubmed, Volltext, DOI [10083]
Vernon C. Br J Clin Pract. Apr 1979; 33(4): 112, 121 Pubmed [3266]
Verny M. Geriatr Psychol Neuropsychiatr Vieil. Jun 2019; 17(2): 189-197 Pubmed [8009]
Veronese ML. J Clin Pharmacol. Aug 2003; 43(8): 831-9 Pubmed [1878]
Veronese ML. J Clin Pharmacol. Oct 2003; 43(10): 1091-100 Pubmed [11961]
Verpooten GA. Br J Clin Pharmacol. Aug 1984; 18(2): 183-93 Pubmed, Volltext [7566]
Verpooten GA. Br J Clin Pharmacol. Aug 1991; 32(2): 187-92 Pubmed, Volltext [4264]
Verrando R. Acta Gastroenterol Belg. Jan 2005; 68(1): 81-5 Pubmed [3459]
Verrico MM. J Am Geriatr Soc. Dec 2000; 48(12): 1659-63 Pubmed [9815]
Verrotti A. Clin Drug Investig. Jan 2018; 38(1): 1-8 Pubmed [11708]
Verrotti A. Epilepsia. Feb 2011; 52(2): 199-211 Pubmed [9884]